Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yanli Capsule
- Development stage
- Phase 2
- Lead developer
- Jiangxi Jiewang Pharmaceutical
- Administration
- Oral
01
Overview
Yanli Capsule (延力胶囊) is a Traditional Chinese Medicine (TCM) product developed by Jiangxi Jiewang Pharmaceutical for the treatment of functional erectile dysfunction, specifically in patients presenting with kidney yang deficiency syndrome. As a botanical combination therapy, it is formulated as an oral capsule. The drug has undergone clinical evaluation in China, including a Phase II trial (CTR20150212) intended to preliminarily assess its safety and efficacy in improving sexual function and alleviating symptoms associated with the depletion of kidney yang.
- Brand names
- Yanli Capsule
- Other names
- Yanli Jiaonang
02
Targets
PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on Yanli Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yanli Capsule.